Welcome to our dedicated page for Coeptis Therapeutics SEC filings (Ticker: COEP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Coeptis Therapeutics Holdings Inc. filings document the issuer’s completed merger-related corporate transition, including the name change to Z Squared Inc. and the surviving operating subsidiary Z Squared OpCo Inc. The record includes Form 8-K material-event reports covering capital-structure changes, governance matters, shareholder voting matters, material agreements, operating and financial results, and clinical or regulatory disclosures connected to Coeptis's biotechnology operations.
Additional filings document security-status and compensation matters, including a Form 25 for removal of warrants from Nasdaq listing and registration and an option repricing and exchange program under the 2022 Equity Incentive Plan. The disclosures also cover capital-structure instruments associated with material agreements.
Z Squared Inc. disclosed an initial insider ownership report for Michelle Ellen Burke, who serves as both a director and Co-Chief Executive Officer. The Form 3 data provided does not list any equity transactions or derivative positions for her and shows no reported buys, sells, or gifts.
Coeptis Therapeutics Holdings Inc reported that Vanguard Capital Management beneficially owned 346,975 shares of common stock, representing 5.57% of the class. The filing shows Vanguard has sole dispositive power over 346,975 shares and sole voting power over 26,244 shares. The disclosure attributes holdings to Vanguard and affiliated divisions and notes the holdings may include shares held by Vanguard funds and managed accounts.
Z Squared, Inc. provided additional details on its previously announced business combination with Coeptis Therapeutics Holdings, Inc. and a related pro rata dividend distribution. The company confirmed that shareholders of record on January 2, 2026 will receive a stock dividend from its subsidiary, Coeptis Holdings, Inc.
Each holder of Z Squared common stock will receive one share of non-transferable Coeptis Holdings, Inc. common stock for every share of Z Squared common stock held. The distribution is being effected on April 27, 2026. Z Squared’s common stock is expected to begin trading on the Nasdaq Global Market under the ticker symbol “ZSQR” on the same date.
The company describes itself as a vertically integrated computing infrastructure business with advanced, distributed computing hardware across North Carolina, South Carolina, and Iowa, supported by power management, real-time analytics, and in-house repair capabilities aimed at operational efficiency and scalability.
Coeptis Therapeutics Holdings, Inc. notified Nasdaq of the removal of its warrants from listing and registration under Section 12(b) via Form 25. The filing states the Exchange and the Issuer complied with rules governing voluntary withdrawal and Nasdaq certified its grounds for the Form 25 filing.
Coeptis Therapeutics Holdings, Inc. filed an 8-K announcing it has completed its business combination with Z Squared Inc. and the combined company has been renamed Z Squared Inc.
The company’s public shares are expected to begin trading on the Nasdaq Global Market under the new ticker symbol “ZSQR” on April 27, 2026. Following the transaction, Z Squared Opco Inc. became a wholly owned subsidiary, and former Z Squared Opco stockholders now own about 85% of the combined company, while legacy Coeptis stockholders own about 15%, with roughly 51.5 million common shares outstanding.
Coeptis Therapeutics Holdings, Inc. files Supplement No. 2 to its S-4 prospectus to incorporate its Annual Report on Form 10-K for the year ended December 31, 2025. The 10-K discloses a net loss of $12,277,192 for 2025 and an accumulated deficit of $109,953,728. The filing states shares outstanding were 6,223,221 as of March 18, 2026 and reports an aggregate market value held by non-affiliates of $28,225,766 based on a $7.80 closing price.
The 10-K details biotech and technology divisions, material collaborations and licenses (including Deverra, Vy-Gen and the University of Pittsburgh), a going-concern explanatory paragraph, financing needs, and a pending merger/spin-out transaction expected to close in Q2 2026. Risk factors include substantial doubt about going concern, the cost and uncertainty of clinical development, reliance on partners, and the need for additional capital.
Coeptis Therapeutics Holdings, Inc. reported that Nasdaq has approved, subject to customary conditions and completion of the proposed merger with Z Squared Inc., the listing of the post-merger company’s common stock on the Nasdaq Global Market under the ticker symbol “ZSQR”.
The new listing is expected to take effect when the merger closes, at which point Z Squared will become a wholly owned subsidiary and Coeptis will change its corporate name to Z Squared Inc. Key closing conditions already satisfied include effectiveness of Coeptis’ registration statement on Form S-4 and shareholder approval of the merger proposals at the January 30, 2026 stockholders’ meeting.
The companies state that the business combination remains subject to remaining customary closing conditions and is expected to close in Q2 2026, though there is no assurance these conditions will be met.
The Vanguard Group filed an Amendment No. 1 to its Schedule 13G/A reporting for Coeptis Therapeutics Holdings Inc. The amendment states beneficial ownership of 0 shares (0%) of Common Stock as disclosed, and explains an internal realignment of Vanguard subsidiaries effective January 12, 2026.
Coeptis Therapeutics Holdings, Inc. registers an offering of 107,500 shares of common stock, pre-funded warrants to purchase 67,500 shares, Series A warrants to purchase 153,125 shares and Series B warrants to purchase 153,125 shares.
This prospectus supplement, dated March 23, 2026, supplements the June 14, 2023 prospectus and attaches the company’s Form 10-K for the year ended December 31, 2025. The supplement states none of the Series A or Series B warrants have been exercised and notes a 20-for-1 reverse stock split effected December 30, 2024. The Form 10-K discloses a going concern paragraph, net loss of $12,277,192 for 2025, accumulated deficit of $109,953,728, shares outstanding of 6,223,221 as of March 18, 2026, and market close price of $11.07 on March 19, 2026.